Cargando…

Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer

BACKGROUND: In triple-negative breast cancer (TNBC), PDL1/PD1-directed immunotherapy is effective in less than 20% of patients. In our preliminary study, we have found CSPG4 to be highly expressed together with PDL1 in TNBCs, particularly those harboring TP53 aberrations. However, the clinical impli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Zhe-Yu, Zheng, Chanjuan, Yang, Jianbo, Ding, Siyu, Tian, Can, Xie, Ning, Xue, Lian, Wu, Muyao, Fu, Shujun, Rao, Zhouzhou, Price, Matthew A., McCarthy, James B., Ouyang, Quchang, Lin, Jizhen, Deng, Xiyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907582/ https://www.ncbi.nlm.nih.gov/pubmed/35280756 http://dx.doi.org/10.3389/fonc.2022.804466

Ejemplares similares

Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance
por: Zheng, Chanjuan, et al.
Publicado: (2023)

Hexokinase 2 Is a Pivot for Lovastatin-induced Glycolysis-to-Autophagy Reprogramming in Triple-Negative Breast Cancer Cells
por: Xue, Lian, et al.
Publicado: (2022)

Nucleolar and Coiled-Body Phosphoprotein 1 Is Associated With Stemness and Represents a Potential Therapeutic Target in Triple-Negative Breast Cancer
por: Chen, Sisi, et al.
Publicado: (2022)

Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer
por: Qadir, Jasiya, et al.
Publicado: (2021)

Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

The regulatory mechanisms of NG2/CSPG4 expression
por: Ampofo, Emmanuel, et al.
Publicado: (2017)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

Impact of TP53 mutations in Triple Negative Breast Cancer
por: Mitri, Zahi I., et al.
Publicado: (2022)

Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer
por: Nicolosi, Pier Andrea, et al.
Publicado: (2015)

Localization and Developmental Expression Patterns of CSPG in the RCS Rat Retina
por: Chen, Li-Feng, et al.
Publicado: (2011)

CSPG4: a prototype oncoantigen for translational immunotherapy studies
por: Rolih, Valeria, et al.
Publicado: (2017)

Cspg4(high) microglia contribute to microgliosis during neurodegeneration
por: Liu, Ya-jing, et al.
Publicado: (2023)

Synthesis of Novel Peptide Dendrimers PDL-GB2 and PDL-G2
por: Yunzhu, Lin, et al.
Publicado: (2015)

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
por: Campo, Elias, et al.
Publicado: (2018)

Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma
por: Feng, Xiangling, et al.
Publicado: (2022)

B‐prolymphocytic leukemia (B‐PLL) with genetic aberrations involving MYC and TP53
por: Tamber, Gurdip Singh, et al.
Publicado: (2021)

Editorial: Triple-negative breast cancer: Heterogeneity, tumor microenvironment and targeted therapy
por: Deng, Xiyun, et al.
Publicado: (2022)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas
por: Schiffer, Davide, et al.
Publicado: (2018)

Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers
por: Zhang, Hongyu, et al.
Publicado: (2022)

Structural basis for CSPG4 as a receptor for TcdB and a therapeutic target in Clostridioides difficile infection
por: Chen, Peng, et al.
Publicado: (2021)

PDL1 Regulation by p53 via miR-34
por: Cortez, Maria Angelica, et al.
Publicado: (2015)

PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC)
por: Ghosh, Joydeep, et al.
Publicado: (2021)

FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients
por: Xie, Ning, et al.
Publicado: (2020)

The clinical characteristics and prognosis in adult Ph negative acute lymphoblastic leukemia with TP53 aberrations
por: Fang, Qiuyun, et al.
Publicado: (2022)

HER2-positive double primary tumor of gastric and breast cancer occur synchronously in a patient: A case report
por: OUYANG, QUCHANG, et al.
Publicado: (2016)

Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma
por: Riccardo, Federica, et al.
Publicado: (2019)

NG2/CSPG4 regulates cartilage degeneration during TMJ osteoarthritis
por: Reed, David A., et al.
Publicado: (2022)

Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma
por: Teppert, Karin, et al.
Publicado: (2023)

A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
por: Wang, Jiayu, et al.
Publicado: (2023)

Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer
por: Sun, Kun, et al.
Publicado: (2023)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer
por: Eustace, Alex J., et al.
Publicado: (2022)

The prognosis and risk factors for capecitabine maintenance treatment in metastatic breast cancer: a retrospective comparative cohort study
por: Tian, Can, et al.
Publicado: (2022)

Establishing the Link between X-Chromosome Aberrations and TP53 Status, with Breast Cancer Patient Outcomes
por: Caramia, Franco, et al.
Publicado: (2023)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Two PTP receptors mediate CSPG inhibition by convergent and divergent signaling pathways in neurons
por: Ohtake, Yosuke, et al.
Publicado: (2016)

CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL
por: Jordaan, Sandra, et al.
Publicado: (2017)

CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
por: Harrer, Dennis C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fcmuhosn51cg03jiki4p4pp9m1